Keywords
COVID-19
Epidemiology
Clinical features
How to Cite
Copyright © | All rights reserved.
The journal holds the exclusive copyright for the publication of this article under the terms of Brazilian law 9610/98.
Partial reproduction
The use of parts of the texts, figures and questionnaire of the article is free, being mandatory the citation of the authors and journal.
Total reproduction
It is expressly prohibited and must be authorized by the journal.
Abstract
Objective: To describe the clinical and epidemiological characteristics of patients hospitalized for Covid-19 in a public hospital in Minas Gerais. Methods: This is an observational, cross-sectional study based on electronic medical records. The population consisted of patients with laboratory confirmation for Covid-19 between March 2020 and March 2021. Demographic data, clinical manifestations and comorbidities were analyzed. Results: 92 patients diagnosed with Covid-19 were included. Most patients were male (62.0%), with a mean age of 58 years. The most prevalent comorbidities were hypertension (40.2%), diabetes (21.7%) and heart disease (9.8%). The most common symptoms were dyspnea (64.1%), fever (48.9%) and dry cough (42.4%). Thirty-seven patients (40.2%) required care in the Intensive Care Unit (ICU), and of these, only one did not receive invasive ventilatory support. The mortality rate at the research institution was 33.7%. Conclusion: According to the data collected, it was observed that the majority of people infected with Covid-19 were male, with an average age of 58 years and with at least one underlying disease. The most prevalent symptoms were dyspnea, fever and dry cough.
References
AHN DG, et al. Current Status of Epidemiology, Diagnosis, Therapeutics, and Vaccines for Novel Coronavirus Disease 2019 (COVID-19). J. Microbiol. Biotechnol., 2020; 30: 313-324.
AKULA SM, MCCUBREY JA. Where are we with understanding of COVID-19?. Adv Biol Regul., 2020; 78: 100738.
ATZRODT CL, et al. A Guide to COVID‐19: a global pandemic caused by the novel coronavirus SARS‐CoV‐2. FEBS J., 2020; 287(17): 3633-3650.
BHATRAJU PK, et al. Covid-19 in Critically Ill Patients in the Seattle Region — Case Series. N Engl J Med., 2020: NEJMoa2004500.
BRASIL. Protocolo de Manejo Clínico da Covid-19 na Atenção Especializada. 2020. Disponível em: https://bvsms.saude.gov.br/bvs/publicacoes/manejo_clinico_covid-19_atencao_especializada.pdf. Acessado em: 22 de janeiro de 2022.
CENTERS FOR DISEASE CONTROL AND PREVENTION. COVID-19 Overview and Infection Prevention and Control Priorities in non-U.S. Healthcare Settings. 2021. Disponível em: https://www.cdc.gov/coronavirus/2019-ncov/hcp/non-us settings/overview/index.html. Acessado em: 21 de março de 2021.
CHAND S, et al. COVID-19-Associated Critical Illness—Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center. Journal of Intensive Care Medicine, 2020; 35(10): 963-970.
CHEN N, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 2020; 395(10223): 507–513.
CHEN Y, et al. Aging in COVID-19: Vulnerability, immunity and intervention. Ageing Res Rev., 2021; 65: 101205.
CHEN Z, et al. Clinical Characteristics of Patients with Severe and Critical COVID-19 in Wuhan: A Single-Center, Retrospective Study. Infect Dis Ther., 2021; 10(1): 421-438.
CHOI A, et al. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants. Journal of Virology, 2021; 95(23): e01313-21.
CORRÊA TD, et al. Clinical characteristics and outcomes of COVID-19 patients admitted to the intensive care unit during the first year of the pandemic in Brazil: a single center retrospective cohort study. Einstein (São Paulo), 2021; 19: 1-10.
FERRANDO C, et al. Características, evolución clínica y factores associados a la mortalidad en UCI de los pacientes críticos infectados por SARS-CoV-2 en Espana: ˜ estúdio prospectivo, de cohorte y multicêntrico. Rev Esp Anestesiol Reanim., 2020; 67(8): 425-437.
GANDHI RT, et al. Mild or Moderate Covid-19. N Engl J Med., 2020; 383: 1757-1766.
GRASSELLI G, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected with SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA, 2020; 323(16): 1574–1581.
HANG JJ, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, 2020; 75: 1730–1741.
HE F, et al. Coronavirus disease 2019: What we know?. J Med Virol., 2020; 92(7): 719-725.
HOSOKI K, et al. Molecular mechanisms and epidemiology of COVID-19 from an allergist’s perspective. J Allergy Clin Immunol., 2020; 146(2): 285-299.
ISER BPM, et al. Definição de caso suspeito da COVID-19: uma revisão narrativa dos sinais e sintomas mais frequentes entre os casos confirmados. Epidemiol. Serv. Saúde, 2020; 29(3): e2019354.
JAILLON S, et al. Sexual Dimorphism in Innate Immunity. Clinical Reviews in Allergy & Immunology, 2019; 56: 308–321.
JIN Y, et al. Virology, Epidemiology, Pathogenesis, and Control of COVID-19. Viruses, 2020; 12: 372.
KHALAF K, et al. SARS-CoV-2: Pathogenesis, and Advancements in Diagnostics and Treatment. Front Immunol., 2020; 11: 1-20.
KHAN M, et al. Epidemiological and clinical characteristics of coronavirus disease (COVID-19) cases at a screening clinic during the early outbreak period: a single-centre study. J Med Microbiol., 2020; 69(8): 1114–1123.
LI X, et al. Clinical characteristics of 25 death cases with COVID-19: A retrospective review of medical records in a single medical center, Wuhan, China. International Journal of Infectious Diseases, 2020; 94: 128–132.
MACIEL EL, et al. Fatores associados ao óbito hospitalar por COVID-19 no Espírito Santo. Epidemiol. Serv. Saúde, 2020; 29: 4.
MATSUNAGA N, et al. Clinical Epidemiology of Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan: Report of the COVID-19 Registry Japan. Clin Infect Dis., 2021; 73(11): e3677–e3689.
PAPANIKOLAOU V, et al. From delta to Omicron: S1-RBD/S2 mutation/deletion equilibrium in SARS-CoV-2 defined variants. Gene, 2022; 814: 146134.
PONTES L, et al. Perfil clínico e fatores associados ao óbito de pacientes COVID-19 nos primeiros meses da pandemia. Esc Anna Nery, 2022; 26: e20210203.
SHEERVALILOU R, et al. COVID‐19 under spotlight: A close look at the origin, transmission, diagnosis, and treatment of the 2019‐nCoV disease. J Cell Physiol., 2020; 235: 8873–8924.
SHEPHERD R, et al. Sexual Dimorphism in Innate Immunity: The Role of Sex Hormones and Epigenetics. Front. Immunol., 2021; 11604000.
SULEYMAN G, et al. Clinical Characteristics and Morbidity Associated With Coronavirus Disease 2019 in a Series of Patients in Metropolitan Detroit. JAMA Network Open. 2020; 3(6): e2012270.
TEICH VD, et al. Características epidemiológicas e clínicas dos pacientes com COVID-19 no Brasil. Einstein (São Paulo), 2020; 18: 1-7.
TREVISOL FS, et al. Assessment of patients with Covid-19 hospitalized in southern Santa Catarina. Rev. Soc. Bras. Med. Trop., 2020; 53: e20200579.
WANG D, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11): 1061-1069.
WANG H, et al. The genetic sequence, origin, and diagnosis of SARS-CoV-2. Eur J Clin Microbiol Infect Dis., 2020; 39(9):1629-1635.
WORD HEALTH ORGANIZATION. WHO Coronavirus (COVID-19) Dashboard. 2022. Disponível em: https://covid19.who.int/. Acessado em: 3 de março de 2022.
XIE J, et al. Characteristics of patients with coronavirus disease (COVID‐19) confirmed using an IgM‐IgG antibody test. J Med Virol., 2020; 92: 2004–2010.
YANG X, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med., 2020; 8(5): 475–481.
YI C, et al. Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies. Cell Mol Immunol., 2020; 17(6): 621-630.
YUAN M, et al. A highly conserved cryptic epitope in the receptor binding domains of SARS-CoV-2 and SARS-CoV. Science, 2020; 368: 630–633.